Plain-English translation of NCT06054776 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Mantle Cell Lymphoma research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study tests a combination of three medications—, , and —to see if they work together to treat mantle cell lymphoma that has come back or stopped responding to earlier treatment. The researchers want to understand how safe this combination is and how many people experience a complete remission (where all signs of cancer disappear). This treatment combines a pill you take twice daily with two intravenous medications given on a specific schedule.
Mantle cell lymphoma is a serious blood cancer, and many people find their cancer stops responding to initial treatments. Doctors need new combinations of medicines that work better and help people live longer, which is why this trial is testing whether these three medications together might be more effective than what's currently available.
You likely qualify if…
You likely don't qualify if…
You would come to the clinic regularly for up to 12 treatment cycles, with each cycle lasting 3 weeks. You'll take the pill medication twice daily at home throughout the study, and receive the two intravenous medications on specific days (the schedule is more frequent at the beginning and then simplifies). During your visits, you'll have blood tests, imaging scans (like CT or PET scans), and possibly heart imaging and bone marrow biopsies to monitor your response. After 12 cycles, if your cancer responds well to treatment, you may continue taking the pill medication alone as part of standard care.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
United States